We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+21.5%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.75B
AUM Growth
+$332M
Cap. Flow
-$28.9M
Cap. Flow %
-0.5%
Top 10 Hldgs %
51.71%
Holding
444
New
223
Increased
65
Reduced
45
Closed
77

Top Buys

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$54.6M
2
KYTX icon
Kyverna Therapeutics
KYTX
+$40.8M
3
SGRY icon
Surgery Partners
SGRY
+$33.8M
4
LRMR icon
Larimar Therapeutics
LRMR
+$33.4M
5
ALHC icon
Alignment Healthcare
ALHC
+$30.6M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$62.6M
2
SWTX
SpringWorks Therapeutics
SWTX
+$60.2M
3
BAX icon
Baxter International
BAX
+$55M
4
VKTX icon
Viking Therapeutics
VKTX
+$36.3M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$28.1M

Sector Composition

Rank Sector Weight
1 Healthcare 88.87%
2 Industrials 0.71%
3 Technology 0.31%
4 Consumer Discretionary 0.26%
5 Financials 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ED icon
251
Consolidated Edison
ED
$41.4B
$297K 0.01%
+3,275
New +$294K
GPI icon
252
Group 1 Automotive
GPI
$4.26B
$294K 0.01%
+1,007
New +$275K
CVGW
253
DELISTED
Calavo Growers
CVGW
$294K 0.01%
+10,574
New +$297K
FRSH icon
254
Freshworks
FRSH
$3.21B
$292K 0.01%
+16,036
New +$332K
CTVA icon
255
Corteva
CTVA
$60.5B
$292K 0.01%
+5,058
New +$261K
BMY icon
256
Bristol-Myers Squibb
BMY
$129B
$291K 0.01%
5,370
-2,892
-35% -$147K
ORI icon
257
Old Republic International
ORI
$10.9B
$290K 0.01%
+9,447
New +$275K
OCUL icon
258
Ocular Therapeutix
OCUL
$1.83B
$290K 0.01%
31,852
+12,865
+68% +$91.3K
TIPT icon
259
Tiptree Inc
TIPT
$687M
$289K 0.01%
+16,728
New +$300K
TRV icon
260
Travelers Companies
TRV
$81.1B
$288K 0.01%
+1,251
New +$267K
DGX icon
261
Quest Diagnostics
DGX
$26B
$287K 0.01%
+2,157
New +$280K
SKIN icon
262
SkinHealth Systems
SKIN
$83.4M
$283K ﹤0.01%
63,835
+48,678
+321% +$158K
HRMY icon
263
Harmony Biosciences
HRMY
$2.08B
$283K ﹤0.01%
+8,420
New +$270K
AMSF icon
264
AMERISAFE
AMSF
$562M
$283K ﹤0.01%
+5,633
New +$280K
FDMT icon
265
4D Molecular Therapeutics
FDMT
$502M
$281K ﹤0.01%
+8,821
New +$225K
JBI icon
266
Janus International
JBI
$702M
$280K ﹤0.01%
18,539
-3,422
-16% -$49.7K
IHRT icon
267
iHeartMedia
IHRT
$531M
$275K ﹤0.01%
131,552
+18,301
+16% +$43.1K
CFLT
268
DELISTED
Confluent
CFLT
$274K ﹤0.01%
+8,962
New +$253K
ANGO icon
269
AngioDynamics
ANGO
$605M
$273K ﹤0.01%
46,591
+31,239
+203% +$186K
OMCL icon
270
Omnicell
OMCL
$1.88B
$272K ﹤0.01%
+9,300
New +$282K
LQDA icon
271
Liquidia Corp
LQDA
$7.72B
$272K ﹤0.01%
+18,429
New +$256K
VEEV icon
272
Veeva Systems
VEEV
$33.8B
$272K ﹤0.01%
+1,172
New +$253K
ABSI icon
273
Absci
ABSI
$1.17B
$269K ﹤0.01%
+47,441
New +$214K
WRB icon
274
W.R. Berkley
WRB
$28.1B
$269K ﹤0.01%
+4,568
New +$247K
BAX icon
275
Baxter International
BAX
$12.8B
$262K ﹤0.01%
6,141
-1,352,545
-100% -$55M
9 10
11
12 13

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2024 Portfolio in Review

As of Q1 2024, Deerfield Management held 444 positions worth $5.75B, up 6.1% from $5.42B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deerfield Management's Q1 2024 filing shows 223 new, 65 increased, 45 reduced and 77 closed positions. Its largest new stake was BioNTech: 569,574 shares worth $52.5M. The largest sale was RayzeBio, Inc. Common Stock, an estimated $62.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 78% a quarter earlier, followed by Industrials and Technology.

  • Deerfield Management's largest Q1 2024 buy was BioNTech: 569,574 shares worth $52.5M.
  • Deerfield Management added most to Surgery Partners in Q1 2024, an estimated $33.8M increase.
  • Deerfield Management's biggest Q1 2024 reduction was SpringWorks Therapeutics, cutting an estimated $60.2M.
  • Deerfield Management fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $62.6M.
  • Deerfield Management's ten largest holdings make up 52% of its $5.75B portfolio in Q1 2024.
  • Deerfield Management opened 223 new positions and closed 77 in Q1 2024.
  • Deerfield Management's portfolio value rose 6.1% quarter-over-quarter to $5.75B.

Based on Deerfield Management's 13F filing for Q1 2024, filed 15 May 2024.